BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 29594945)

  • 21. Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population.
    Li L; Dang Q; Xie H; Yang Z; He D; Liang L; Song W; Yeh S; Chang C
    Oncotarget; 2015 Jun; 6(16):14179-90. PubMed ID: 25895025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR).
    Bonaccorsi L; Carloni V; Muratori M; Formigli L; Zecchi S; Forti G; Baldi E
    Int J Cancer; 2004 Oct; 112(1):78-86. PubMed ID: 15305378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
    Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. From transforming growth factor-beta signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells.
    Kang HY; Lin HK; Hu YC; Yeh S; Huang KE; Chang C
    Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3018-23. PubMed ID: 11248024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgen receptor inhibits epithelial-mesenchymal transition, migration, and invasion of PC-3 prostate cancer cells.
    Huo C; Kao YH; Chuu CP
    Cancer Lett; 2015 Dec; 369(1):103-11. PubMed ID: 26297988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
    Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
    J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells.
    Wen S; Niu Y; Lee SO; Yeh S; Shang Z; Gao H; Li Y; Chou F; Chang C
    Mol Carcinog; 2016 Dec; 55(12):2278-2290. PubMed ID: 26894509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion.
    Shih TC; Liu R; Wu CT; Li X; Xiao W; Deng X; Kiss S; Wang T; Chen XJ; Carney R; Kung HJ; Duan Y; Ghosh PM; Lam KS
    Clin Cancer Res; 2018 Sep; 24(17):4319-4331. PubMed ID: 29666302
    [No Abstract]   [Full Text] [Related]  

  • 29. Endothelial cells enhance prostate cancer metastasis via IL-6→androgen receptor→TGF-β→MMP-9 signals.
    Wang X; Lee SO; Xia S; Jiang Q; Luo J; Li L; Yeh S; Chang C
    Mol Cancer Ther; 2013 Jun; 12(6):1026-37. PubMed ID: 23536722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infiltrated pre-adipocytes increase prostate cancer metastasis via modulation of the miR-301a/androgen receptor (AR)/TGF-β1/Smad/MMP9 signals.
    Xie H; Li L; Zhu G; Dang Q; Ma Z; He D; Chang L; Song W; Chang HC; Krolewski JJ; Nastiuk KL; Yeh S; Chang C
    Oncotarget; 2015 May; 6(14):12326-39. PubMed ID: 25940439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality.
    Bluemn EG; Spencer ES; Mecham B; Gordon RR; Coleman I; Lewinshtein D; Mostaghel E; Zhang X; Annis J; Grandori C; Porter C; Nelson PS
    Mol Cancer Res; 2013 Jun; 11(6):568-78. PubMed ID: 23493267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cell cycle regulator cdk2ap1 inhibits prostate cancer cell growth and modifies androgen-responsive pathway function.
    Zolochevska O; Figueiredo ML
    Prostate; 2009 Oct; 69(14):1586-97. PubMed ID: 19585490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes.
    Olsen JR; Azeem W; Hellem MR; Marvyin K; Hua Y; Qu Y; Li L; Lin B; Ke X; Øyan AM; Kalland K
    BMC Cancer; 2016 Jul; 16():377. PubMed ID: 27378372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells.
    Bhuiyan MM; Li Y; Banerjee S; Ahmed F; Wang Z; Ali S; Sarkar FH
    Cancer Res; 2006 Oct; 66(20):10064-72. PubMed ID: 17047070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
    Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A
    Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgen receptor non-nuclear regulation of prostate cancer cell invasion mediated by Src and matriptase.
    Zarif JC; Lamb LE; Schulz VV; Nollet EA; Miranti CK
    Oncotarget; 2015 Mar; 6(9):6862-76. PubMed ID: 25730905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.
    Brizzolara A; Benelli R; Venè R; Barboro P; Poggi A; Tosetti F; Ferrari N
    Cancer Lett; 2017 Aug; 400():9-17. PubMed ID: 28450158
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ASC-J9
    Lin W; Luo J; Sun Y; Lin C; Li G; Niu Y; Chang C
    Cancer Lett; 2018 Jul; 425():21-30. PubMed ID: 29425687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interplay between orphan nuclear receptors and androgen receptor-dependent or-independent growth signalings in prostate cancer.
    Wang Y; Gao W; Li Y; Chow ST; Xie W; Zhang X; Zhou J; Chan FL
    Mol Aspects Med; 2021 Apr; 78():100921. PubMed ID: 33121737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.
    Godoy-Tundidor S; Hobisch A; Pfeil K; Bartsch G; Culig Z
    Clin Cancer Res; 2002 Jul; 8(7):2356-61. PubMed ID: 12114440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.